|Table of Contents|

Observation of curative effect of transarterial infusion of elemene combined with transcatheter arterial chemoembolization for unresectable liver cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 03
Page:
455-458
Research Field:
Publishing date:

Info

Title:
Observation of curative effect of transarterial infusion of elemene combined with transcatheter arterial chemoembolization for unresectable liver cancer
Author(s):
WANG Youjin; GUO Shanfeng; MA Kun; LIANG Ding
Radiology Department，the Affiliated Hospital of Nanjing University of Chinese Medicine，Jiangsu Nanjing 210029，China.
Keywords:
liver cancer; elemene injection; transcatheter arterial chemoembolization; interventional therapy
PACS:
R735.7
DOI:
10.3969/j.issn.1672-4992.2021.03.020
Abstract:
Objective：To observe the short term efficacy and adverse reactions of transarterial infusion of elemene combined with transcatheter arterial chemoembolization for unresectable liver cancer.Methods：48 cases of patients with unresectable liver cancer in our hospital from January 2015 to October 2016，were randomly divided into observation group(24 cases) and control group(24 cases).Patients in control group were treated with transcatheter arterial chemoembolization(TACE) using raltitrexed(3 mg/m2) combined with oxaliplatin(100 mg/m2) and epirubicin(40 mg/m2)，while patients in observation group were treated with hepatic arterial infusion of elemene（200~400 mg/m2） combined with TACE using raltitrexed(3 mg/m2) combined with oxaliplatin(100 mg/m2) and epirubicin(40 mg/m2).Repeated treatment was given every 4~6 weeks.The end of the follow-up period was October 31，2018.The response rate(RR)，disease control rate(DCR)，progression free survival(PFS) and the adverse effects were assessed，and the results were compared between the two groups.Results：The RR of the observation group and control group were 66.67% and 58.33% respectively.The DCR of the observation group and control group were 87.50% and 83.33% respectively.Both the differences between the two groups were not statistically significant(P>0.05).The mean progression free survival of the observation group and control group were （10.69±1.00） months and （7.68±1.03） months respectively.And the difference was statistically significant(P<0.05).The adverse reactions in the two groups were mainly abdominal pain，nausea，vomiting，myelosuppression，fever and elevation of transaminase.There were statistically significant differences in the incidence of fever，nausea and vomiting，and myelosuppression between the two groups(P<0.05).There were not significant differences in the incidence of abdominal pain and transaminase elevation(P>0.05).Conclusion：Transarterial infusion of elemene combined with TACE for the treatment of unresectable liver cancer is safe and feasible，and can reduce the adverse reactions after TACE and prolong the average PFS.

References:

[1]LLOVET JM，VILLANUEVA A，LACHENMAYER A，et al.Advances in targeted therapies for hepatocellular carcinoma in the genomic era［J］.Nat Rev Clin Oncol，2015，12(7)：408-424.
[2]FORNER A，REIG ME，DE LOPE CR，et al.Current strategy for staging and treatment：The BCLC update and future prospects［J］.Semin Liver Dis，2010，30(1)：61-74.
[3]张永军，张爱琴，包文龙，等．榄香烯抑制p21基因表达逆转肺癌化疗耐药的实验研究［J］．中华中医药学刊，2015，33(12)：2957-2960. ZHANG YJ，ZHANG AQ，BAO WL，et al.Experimental study of elemene reversing lung cancer cells' chemotherapy drug resistance by restraining p21 gene expression［J］.Chinese Archives of Traditional Chinese Medicine，2015，33(12)：2957-2960.
[4]LI JY，YU J，LIU A，et al．β-elemene against human lung cancer via up-regulation of p53 protein expression to promote the release of exosome［J］.Lung Cancer，2014，86(2)：144-150.
[5]王一喆，胡雪君.β-榄香烯治疗晚期非小细胞肺癌的临床应用现状及研究进展［J］.现代肿瘤医学，2018，26(10)：1643-1646. WANG YZ，HU XJ.Synergistic effect of β-elemene on varies of treatments for patients with advanced non-small cell lung cancer［J］. Modern Oncology，2018，26(10)：1643-1646.
[6]中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)［J］．临床肝胆病杂志，2011，27（11）：1141-1159. Ministry of Health of the People's Republic of China.Diagnosis，management，and treatment of hepatocellular carcinoma(V2011)［J］.J Clini Hepatol，2011，27(11)：1141-1159.
[7]EDELINE J，BOUCHER E，ROLLAND Y，et al.Comparison of tumor response by response evaluation criteria in solid tumors(RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma［J］.Cancer，2012，118(1)：147-156.
[8]TALENFELD AD，SISTA AK，MADOFF DC． Transarterial therapies for primary liver tumors［J］．Surg Oncol Clin N Am，2014，23(2)：323-351.
[9]MAO Y，ZHANG J，HOU L，et al．The effect of beta-elemene on alpha-tubulin polymerization in human hepatoma HepG2 cells［J］.Chin J Cancer Res，2013，25(6)：770-776.
[10]LIU JS，HE SC，ZHANG ZL，et al．Anticancer effects of β-elemene in gastric cancer cells and its potential underlying proteins：a proteomic study［J］．Oncol Rep，2014，32(6)：2635-2647.
[11]张莉娜，陈恳，钱俐，等.榄香烯乳对人胰腺癌移植瘤组织中凋亡相关蛋白表达的影响［J］.世界华人消化杂志，2014，22(17)：2385-2392. ZHANG LN，CHEN K，QIAN L，et al.Effect of treatment with elemene on expression of apoptosis-related proteins in pancreatic carcinoma xenografts in nude mice［J］.World Chinese Journal of Digestology，2014，22(17)：2385-2392.
[12]朱琳芳，王秋岩，吴慧丽，等.榄香烯抗肿瘤活性机理及其衍生物活性研究进展［J］.杭州师范大学学报（自然科学版），2018，17(2)：170-176. ZHU LF，WANG QY，WU HL，et al.Research progress of mechanism in antitumor activity of elemene and its derivatives［J］.Journal of Hangzhou Normal University(Natural Sciences Edition)，2018，17(2)：170-176.
[13]李慧乐，莫传伟，赵春辉，等.莪术提取物榄香烯对肝癌H22荷瘤小鼠的抑瘤作用［J］.中国临床药理学杂志，2018，34(11)：1345-1348. LI HL，MO CW，ZHAO CH，et al.Antitumor effect of elemene from rhizoma curcuma on hepatoma H22 tumor bearing mice［J］.The Chinese Journal of Clinical Pharmacology，2018，34(11)：1345-1348.
[14]郑瑾，刘强，任凯夕，等．β-榄香烯对肝癌细胞SK-hep-1的迁移和侵袭力的影响［J］．现代肿瘤医学，2009，17(11)：2054-2058. ZHENG J，LIU Q，REN KX，et al.Migratory and invasive ability of hepatocellular carcinoma cell line SK-hep-1 effected by β-elemene［J］.Journal of Modern Oncology，2009，17(11)：2054-2058.
[15]陈德连，江会红．榄香烯联合介入治疗中晚期肝癌患者的近期疗效［J］.广州中医药大学学报，2016，33(1)：27-30. CHEN DL，JIANG HL.Short-term therapeutic effect of elemene combined with interventional therapy for moderate and advanced liver cancer［J］.Journal of Guangzhou University of Traditional Chinese Medicine，2016，33(1)：27-30.

Memo

Memo:
-
Last Update: 2020-12-31